Bile Duct Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2014-09-09
Clinical Trial Update: Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery [Phase 2]
A Phase 2 study of selumetinib combined with MK-2206 for refractory or advanced gallbladder and biliary tract cancers has been withdrawn.